Proof Of Concept : Immunogenicity and Safety of hepB Injection in the Dermis Using VAX-ID

NCT02186977 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis B

Interventions

DEVICE: VAX-ID
DRUG: 1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)
DRUG: 0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD)

Sponsor

Novosanis NV